The U.S. Food and Drug Administration (FDA) has proposed a new policy that reduces premarket notification requirements related to devices that have had their safety and efficacy well proven, for example, blood clotting tests and common urine and blood tests. Read more.
© 2020 HealthCom Media
All rights reserved. No part of this website or publication may be reproduced, stored, or transmitted in any form or by any means, electronic or mechanical, including photocopy, recording, or any information storage and retrieval system, without permission in writing from the copyright holder